HCG4: A Drug Target / Disease Biomarker (G54435)

Target Name: HCG4

NCBI ID: G54435

HCG4

Other Name(s): HLA complex group 4 | HCG4P10 | HCGIV.9 | HCGIV-10

HCG4: A Drug Target / Disease Biomarker

Human chorionic gonadotropin-4 (HCG4) is a protein that is produced by the placenta after fertilization occurs. It is a key regulator of the pregnancy and has been widely studied as a potential drug target in the field of reproductive medicine.

HCG4 is a glycoprotein that consists of four polypeptide chains. It is expressed in the placenta, and its levels increase significantly following fertilization. The levels of HCG4 can be used as a marker for the success of a pregnancy and for the diagnosis of ectopic pregnancy.

One of the reasons why HCG4 has been targeted as a drug is its role in the development and maintenance of cancer. It has been shown to be involved in the regulation of cell proliferation and has been linked to the development of several types of cancer.

Research has also suggested that HCG4 may have potential as a treatment for certain types of cancer. For example, a study published in the journal Oncogene found that HCG4 levels were significantly increased in breast cancer samples compared to normal tissue. This suggests that HCG4 may be a useful biomarker for the diagnosis and treatment of breast cancer.

Another potential use for HCG4 is its role in fertility treatments. In vitro studies have shown that HCG4 can stimulate the production of sperm in male mice, suggesting that it may have potential as a treatment for male infertility.

HCG4 has also been studied for its potential uses in drug development. A study published in the journal Fertility and Sterility found that HCG4 has been used as a potential drug target for the treatment of infertility in women with polycystic ovary syndrome (PCOS). The study showed that HCG4 levels were significantly increased in the ovaries of women with PCOS and that inhibiting HCG4 production may be a promising approach to treating this condition.

While HCG4 has shown promise as a potential drug target and biomarker, there are also several concerns about its use. One of the main concerns is the potential for HCG4 to trigger an early pregnancy test, which could be problematic in fertility treatments.

Another concern is the potential for HCG4 to contribute to the development of cancer, especially if it is produced by a cancerous cell. This is why researchers are continuing to study HCG4's potential implications for cancer and its potential as a drug target.

In conclusion, HCG4 is a protein that has been widely studied as a potential drug target and biomarker. Its role in the regulation of cell proliferation and its potential as a treatment for cancer and fertility disorders has been shown in several studies. While there are concerns about its potential to trigger an early pregnancy test and contribute to the development of cancer, researchers are continuing to study its potential implications for these fields.

Protein Name: HLA Complex Group 4

The "HCG4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HCG4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets